Japanese Encephalitis Vaccine
Commercial- Indications
- Japanese Encephalitis
Company intelligence / Profile preview
Intercell AG
Vienna, Vienna, Austriaintercell.events ↗
- Ownership
- Private
- Employees
- ~400
- Development stage
- Commercial
01
Overview
Had one marketed product (IXIARO/JESPECT for Japanese Encephalitis) and multiple candidates in clinical development
- Therapeutic areas
- Infectious Diseases
- Modalities
- Vaccinesmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Intercell AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Intercell AG.